# Pathogenic role of ILC2 in rheumatoid arthritis

> **NIH NIH R21** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2020 · $207,955

## Abstract

ABSTRACT
The pathogenesis of rheumatoid arthritis (RA) involves a complex interplay between adaptive (e.g. T & B cells)
and innate (e.g. macrophages) immune cells and mesenchymal-derived stromal cells (e.g. local fibroblast-like
synoviocytes [FLS]). Immune cell-mediated activation of FLS plays a key role in joint inflammation and
destruction during RA. This project will explore a novel mechanism of activation of FLS by the ILC2 subset of
innate lymphoid cells (ILCs). ILCs are recently discovered immune cells that are enriched in peripheral tissues
and act as the first local barrier against infections and tumors. Four major subsets of ILCs have been identified,
ILC1, ILC2, ILC3 and cNK cells that display immune functions similar to those of Th1, Th2, and Th17 subsets
of CD4 T cells and CD8 killer T cells respectively. Of these, ILC2 are homologous to Th2 cells and secrete
“type 2 cytokines” such as interleukin-4 (IL-4), IL-5 and IL-13, which drive a “type 2” immune response. The
type 2 immune response is considered to be anti-inflammatory in RA, however it remains unclear whether ILC2
exclusively play a disease protective role in RA. The objective of this grant is to collect pilot evidence that ILC2
play a pathogenic role in RA by secreting an epidermal growth factor (EGF)-similar molecule called
amphiregulin (AREG). ILC2 are known to secrete AREG which normally helps to maintain tissue integrity in
response to infections, but is also implicated in the pathogenesis of organ fibrosis in the context of chronic
inflammation. We have found high levels of AREG -mainly produced by ILC2- in the joints of arthritic mice and
have preliminary evidence that AREG promotes arthritis severity and the aggressive behavior of fibroblast-like
synoviocytes (FLS) in vitro. We thus hypothesize that joint-localized ILC2 promote disease activity in RA
through interaction with FLS via production of AREG. This grant application proposes experiments aimed to
obtain rigorous evidence that ILC2 enhance development of arthritis in mice through production of AREG (Aim
1), and that AREG promotes aggressive and joint-destructive behavior in FLS in vitro and in vivo (Aim 2). The
project fits well with the R21 format because the objective is to collect pilot evidence in support of a concept
that is currently considered high risk and potentially counterintuitive, however, if validated, it might pave the
way to novel therapeutic approaches to RA via interference with the ILC2-AREG-FLS axis.
.

## Key facts

- **NIH application ID:** 10057498
- **Project number:** 1R21AR076578-01A1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** GARY S FIRESTEIN
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $207,955
- **Award type:** 1
- **Project period:** 2020-09-24 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10057498

## Citation

> US National Institutes of Health, RePORTER application 10057498, Pathogenic role of ILC2 in rheumatoid arthritis (1R21AR076578-01A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10057498. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*